Mauro Ferrari Net Worth

The estimated Net Worth of Mauro Ferrari is at least $2.89 Million dollars as of 11 January 2024. Mauro Ferrari owns over 3,147 units of Arrowhead Pharmaceuticals stock worth over $1,272,691 and over the last 11 years he sold ARWR stock worth over $1,317,206. In addition, he makes $302,169 as Independent Director at Arrowhead Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mauro Ferrari ARWR stock SEC Form 4 insiders trading

Mauro has made over 5 trades of the Arrowhead Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 3,147 units of ARWR stock worth $119,775 on 11 January 2024.

The largest trade he's ever made was selling 17,756 units of Arrowhead Pharmaceuticals stock on 26 June 2019 worth over $490,243. On average, Mauro trades about 2,440 units every 250 days since 2013. As of 11 January 2024 he still owns at least 60,778 units of Arrowhead Pharmaceuticals stock.

You can see the complete history of Mauro Ferrari stock trades at the bottom of the page.

Mauro Ferrari biography

Dr. Mauro Ferrari Ph.D. serves as Independent Director of the Company. Dr. Ferrari currently serves as Affiliate professor of Pharmaceutics at the University of Washington in Seattle, WA. He also currently serves as President of the European Research Council. From 2010 to 2019, Dr. Ferrari was President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), Executive Vice President of Houston Methodist Hospital and Senior Associate Dean of Weill Cornell Medical College in New York. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology and Fellow, US National Academy of Inventors. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at UC Berkeley and The Ohio State University.

What is the salary of Mauro Ferrari?

As the Independent Director of Arrowhead Pharmaceuticals, the total compensation of Mauro Ferrari at Arrowhead Pharmaceuticals is $302,169. There are 12 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.

How old is Mauro Ferrari?

Mauro Ferrari is 60, he's been the Independent Director of Arrowhead Pharmaceuticals since 2010. There are 4 older and 12 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.

What's Mauro Ferrari's mailing address?

Mauro's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.

Insiders trading at Arrowhead Pharmaceuticals

Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.

What does Arrowhead Pharmaceuticals do?

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Complete history of Mauro Ferrari stock trades at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals executives and stock owners

Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include:

• Christopher Anzalone,
  President, Chief Executive Officer, Director
• Kenneth Myszkowski,
  Chief Financial Officer
• Dr. Christopher R. Anzalone,
  CEO, Pres & Director
• Patrick O'Brien,
  General Counsel
• Kenneth A. Myszkowski,
  Chief Financial Officer
• Dr. Javier San Martin M.D.,
  Chief Medical Officer
• Dr. Javier San Martin,
  Chief Medical Officer
• Douglass Given,
  Chairman of the Board
• Michael Perry,
  Lead Independent Director
• James Hassard,
  Chief Commercial Officer
• Dr. Bruce D. Given,
  Advisor
• William Waddill,
  Independent Director
• Mauro Ferrari,
  Independent Director
• Vincent Anzalone,
  IR Contact Officer
• Oye Olukotun,
  Independent Director
• Marianne De Backer,
  Independent Director
• Javier San Martin,
  Chief Medical Officer
• James Hassard,
  Chief Commercial Officer
• Curt Bradshaw,
  Chief Scientific Officer
• Dr. Mark Seefeld,
  Head of Toxicology & VP
• Dr. James C. Hamilton,
  Sr. VP of Discovery & Translational Medicine
• Patrick O'Brien,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Howard Lovy,
  Director of Communications
• Jane Davidson,
  Head of HR & Admin., VP and Corp. Sec.
• Dr. Mark M. Davis,
  Founder and Founder & Director of Insert Therapeutics Inc & Calando
• Bruce D Given,
  Chief Operating Officer
• Edward W Frykman,
  Director
• David M Knott,
  10% owner
• Douglas B Given,
  Director
• David L. Lewis,
  Chief Scientific Officer
• Joseph Theodore Iii Kingsley,
  Chief Financial Officer
• Zhen Li,
  Snr. VP, Chem and Non-Clin Dev
• Peter Brian Leone,
  VP, Strategy & Program Mgmt
• Victoria Vakiener,
  Director
• Leon Ekchian,
  President
• Marshall Robert Ching,
  10% owner
• James M Jr Phillips,
  Secretary
• Charles Mc Kenney,
  Director
• R Bruce Stewart,
  President
• Leroy T Rahn,
  Director
• Paul Clayton Mc Donnel,
  Chief Financial Officer
• James C Hamilton,
  Chief Discovery/Trans Medicine
• Hongbo Lu,
  Director
• Tracie Oliver,
  Chief Commercial Officer